
Dirk Hellwig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3858917/publications.pdf Version: 2024-02-01



DIDE HELLWIC

#	Article	IF	CITATIONS
1	Diagnostic value of FDG PET/CT imaging in patients with surgically managed infective endocarditis: results of a retrospective analysis at a tertiary center. Journal of Nuclear Cardiology, 2022, 29, 1191-1204.	1.4	9
2	Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model. Oncotarget, 2021, 12, 37-48.	0.8	4
3	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. Nature Communications, 2021, 12, 1439.	5.8	39
4	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3550-3559.	3.3	21
5	Hope for new developments in the reimbursement of oncological PET/CT in Germany. Nuklearmedizin - NuclearMedicine, 2021, 60, 205-208.	0.3	5
6	Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's Disease. Frontiers in Pharmacology, 2021, 12, 599561.	1.6	11
7	Lemierre's syndrome following infectious mononucleosis: an unusual reason for neck pain. Lancet Infectious Diseases, The, 2021, 21, 1050.	4.6	2
8	Dose estimates of occupational radiation exposure during radioguided surgery of Tc-99m-PSMA-labeled lymph nodes inÂrecurrent prostate cancer. Nuklearmedizin - NuclearMedicine, 2021, 60, 425-433.	0.3	0
9	Non-Invasive Prediction of IDH Mutation in Patients with Clioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning. Cancers, 2020, 12, 3406.	1.7	17
10	FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview. Cancers, 2020, 12, 601.	1.7	33
11	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1765-1771.	2.8	34
12	Candida Endocarditis in Patients with Candidemia: A Single-Center Experience of 14 Cases. Mycopathologia, 2020, 185, 1057-1067.	1.3	11
13	Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial. Blood, 2020, 136, 33-34.	0.6	0
14	Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma. Blood, 2019, 134, 2892-2892.	0.6	2
15	CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma. Blood, 2019, 134, 2900-2900.	0.6	1
16	Cutaneous Manifestation of Sarcoidosis in Lower-Back Tattoo With Increased Uptake of 18F-FDG. Clinical Nuclear Medicine, 2018, 43, 454-455.	0.7	9
17	PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma. Seminars in Nuclear Medicine, 2018, 48, 28-36.	2.5	22
18	In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT. EJNMMI Research, 2018, 8, 98.	1.1	26

DIRK HELLWIG

#	Article	IF	CITATIONS
19	Fluorescence-guidance in non-Gadolinium enhancing, but FET-PET positive gliomas. Clinical Neurology and Neurosurgery, 2018, 172, 177-182.	0.6	18
20	Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment. Oncotarget, 2018, 9, 18844-18857.	0.8	9
21	AIDS-Related Central Nervous System Toxoplasmosis With Increased 18F-Fluoroethyl-I-Tyrosine Amino Acid PET Uptake Due to LAT1/2 Expression of Inflammatory Cells. Clinical Nuclear Medicine, 2017, 42, e506-e508.	0.7	10
22	Epileptic Activity Increases Cerebral Amino Acid Transport Assessed by ¹⁸ F-Fluoroethyl-I-Tyrosine Amino Acid PET: A Potential Brain Tumor Mimic. Journal of Nuclear Medicine, 2017, 58, 129-137.	2.8	45
23	Differentiated Thyroid Cancer—Treatment: State of the Art. International Journal of Molecular Sciences, 2017, 18, 1292.	1.8	123
24	Effect of lifelong antibiotic treatment for aortic arch prosthesis infection. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 844-845.	0.5	0
25	Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. Journal of Clinical Oncology, 2017, 35, 7506-7506.	0.8	21
26	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clinical Research in Cardiology, 2016, 105, 364-371.	1.5	54
27	Biomodulatory metronomic therapy induces <scp>PET</scp> â€negative remission in chemo―and brentuximabâ€refractory Hodgkin lymphoma. British Journal of Haematology, 2016, 172, 290-293.	1.2	20
28	ls reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson's disease?. Journal of Neurology, 2014, 261, 45-51.	1.8	11
29	Nuclear medicine training and practice in Germany. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 187-190.	3.3	5
30	Combined PET/MR: Where Are We Now? Summary Report of the Second International Workshop on PET/MR Imaging April 8–12, 2013, Tubingen, Germany. Molecular Imaging and Biology, 2014, 16, 295-310.	1.3	38
31	Evaluation of transcranial sonographic findings and MIBG cardiac scintigraphy in the diagnosis of idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 995-999.	1.1	8
32	Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer. Nuklearmedizin - NuclearMedicine, 2012, 51, 101-110.	0.3	25
33	Myocardial MIBG scintigraphy may predict the course of motor symptoms in Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 372-375.	1.1	11
34	F-18-FDG-PET Confined Radiotherapy of Locally Advanced NSCLC With Concomitant Chemotherapy: Results of the PET-PLAN Pilot Trial. International Journal of Radiation Oncology Biology Physics, 2011, 81, e283-e289.	0.4	41
35	Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors. Nuklearmedizin - NuclearMedicine, 2011, 50, 39-47.	0.3	7
36	Simultaneous Occurrence of Typical Carcinoid and Non–Small-Cell Lung Cancer in the Same Lung Lobe. Clinical Nuclear Medicine, 2011, 36, 481-483.	0.7	1

DIRK HELLWIG

#	Article	IF	CITATIONS
37	Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 856-864.	3.3	6
38	Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. Pneumologie, 2011, 65, 39-59.	0.1	133
39	FP-CIT SPECT Does Not Predict the Progression of Motor Symptoms in Parkinson's Disease. European Neurology, 2011, 65, 187-192.	0.6	14
40	Brain Tumor Imaging Using p-[123I]Iodo-L-Phenylalanine and SPECT. , 2011, , 215-226.		0
41	Risk stratification of solitary pulmonary nodules by means of PET using 18F-fluorodeoxyglucose and SUV quantification. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1087-1094.	3.3	84
42	Prospective study of p-[1231]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2344-2353.	3.3	13
43	Nonrigid Versus Rigid Registration of Thoracic ¹⁸ F-FDG PET and CT in Patients with Lung Cancer: An Intraindividual Comparison of Different Breathing Maneuvers. Journal of Nuclear Medicine, 2009, 50, 1921-1926.	2.8	24
44	FDG-PET–Based Radiotherapy Planning in Lung Cancer: Optimum Breathing Protocol and Patient Positioning—An Intraindividual Comparison. International Journal of Radiation Oncology Biology Physics, 2009, 73, 103-111.	0.4	44
45	FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin - NuclearMedicine, 2009, 48, 59-69, quiz N8-9.	0.3	23
46	Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-α-methyl-tyrosine for SPECT imaging of gliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 24-31.	3.3	25
47	A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1989-1999.	3.3	140
48	[18F]-FDG–PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Annals of Oncology, 2008, 19, 1619-1623.	0.6	89
49	PET Imaging With p-[I-124]iodo-l-phenylalanine as a New Tool for Diagnosis and Postoperative Control in Patients With Glioma. Clinical Nuclear Medicine, 2008, 33, 441-442.	0.7	10
50	18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense?. Journal of Nuclear Medicine, 2007, 48, 1761-1766.	2.8	167
51	Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Movement Disorders, 2007, 22, 1004-1008.	2.2	91
52	Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 453-462.	3.3	85
53	Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. Journal of Neural Transmission, 2007, 114, 331-335.	1.4	143
54	Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. The Open Neurology Journal, 2007, 1, 1-4.	0.4	11

DIRK HELLWIG

#	Article	IF	CITATIONS
55	Diagnostic performance and prognostic impact of FDC-PET in suspected recurrence of surgically treated non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 13-21.	3.3	124
56	Transcranial sonography and [1231]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain, 2006, 129, 1188-1193.	3.7	124
57	Validation of brain tumour imaging with p-[1231]iodo-l-phenylalanine and SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1041-1049.	3.3	19
58	Radioiodinated phenylalanine derivatives to image pancreatic cancer: a comparative study with [18F]fluoro-2-deoxy-d-glucose in human pancreatic carcinoma xenografts and in inflammation models. Nuclear Medicine and Biology, 2005, 32, 137-145.	0.3	15
59	Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. Journal of Nuclear Medicine, 2005, 46, 1342-8.	2.8	444
60	Progressive dementia caused by Hashimoto's encephalopathy - report of two cases. European Journal of Neurology, 2004, 11, 711-713.	1.7	25
61	Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. Journal of Thoracic and Cardiovascular Surgery, 2004, 128, 892-899.	0.4	87
62	p -[123 I]iodo-l-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancreatic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 532-541.	3.3	15
63	Action and efficacy of p-[131I]iodo-L-phenylalanine on primary human glioma cell cultures and rats with C6-gliomas. Anticancer Research, 2004, 24, 3971-6.	0.5	13
64	Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Annals of Thoracic Surgery, 2003, 75, 231-236.	0.7	112
65	Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma. Clinical Nuclear Medicine, 2002, 27, 781-784.	0.7	11
66	Initial evaluation of the feasibility of single photon emission tomography with p-[1231]iodo-L-phenylalanine for routine brain tumour imaging. Nuclear Medicine Communications, 2002, 23, 121-130.	0.5	23
67	2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography in Target Volume Definition for Radiotherapy of Patients with Non-Small-Cell Lung Cancer. Molecular Imaging and Biology, 2002, 4, 257-263.	1.3	37
68	Clinical Value of Iodine-123-Alpha-Methyl- <scp>l</scp> -Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up. Journal of Clinical Oncology, 2002, 20, 396-404.	0.8	55
69	Comparison of Early Pulmonary Changes in ¹⁸ FDG-PET and CT after Combined Radiochemotherapy for Advanced Non-Small-Cell Lung Cancer: A Study in 15 Patients. , 2001, 37, 26-33.		9
70	Influence of diabetes mellitus on regional cerebral glucose metabolism and regional cerebral blood flow. Nuclear Medicine Communications, 2000, 21, 19-29.	0.5	48
71	Neuropsychological Impairment Correlates With Hypoperfusion and Hypometabolism but Not With Severity of White Matter Lesions on MRI in Patients With Cerebral Microangiopathy. Stroke, 1999, 30, 556-566.	1.0	166
72	18F-Deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. International Journal of Radiation Oncology Biology Physics, 1999, 44, 593-597.	0.4	338

#	Article	IF	CITATIONS
73	F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer Radiology, 1994, 192, 79-86.	3.6	215
74	Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose. Nuclear Medicine Communications, 1993, 14, 596-601.	0.5	49